Pulmonary hypertension: clinical

Thematic Poster
Chairs: S. Sahay (Houston, United States of America), S. Wort (London, United Kingdom), J. Barberà (Barcelona, Spain), O. Sitbon (Le Kremlin-Bicêtre, France)

Characteristics of Japanese elderly patients with pulmonary arterial hypertension Y. Takahashi (Chiba, Japan), K. Yamamoto (Chiba, Japan), N. Tanabe (Chiba, Japan), R. Suda (Chiba, Japan), A. Naito (Chiba, Japan), H. Kasai (Chiba, Japan), R. Nishimura (Chiba, Japan), T. Jujo Sanada (Chiba, Japan), T. Sugiura (Chiba, Japan), A. Shigeta (Chiba, Japan), S. Sakao (Chiba, Japan), K. Tatsumi (Chiba, Japan)
Characteristics of patients treated for pulmonary arterial hypertension in real-world database representing a large US health plan J. Pruett (South San Francisco, CA, United States of America), M. Hull (Eden Prairie, MN, United States of America), C. Elliott (Eden Prairie, MN, United States of America), Y. Tsang (South San Francisco, CA, United States of America), W. Drake (South San Francisco, CA, United States of America)
Impact of pulmonary hypertension (PH) on healthcare resource utilization and costs in patients with portal hypertension S. Sahay (Houston, United States of America), Y. Tsang (South San Francisco, United States of America), M. Flynn (South San Francisco, United States of America), R. Dufour (South San Francisco, United States of America), W. Drake (South San Francisco, United States of America)
Safety, tolerability, pharmacokinetics and pharmacodynamics after repeated once or twice daily RVT-1201, a TPH inhibitor for treatment of PAH S. Wring (Durham, United States of America), J. Rurka (Durham, United States of America), K. Crizer (Durham, United States of America), M. Palacios (Durham, United States of America), M. Snyder (Durham, United States of America), L. Keller (Durham, United States of America), P. Evans (Nottingham, United Kingdom), D. Carpenter (Durham, United States of America)
A phase 1, single-center, open-label, dose-rising clinical trial to evaluate the pharmacokinetics, safety and tolerability of treprostinil inhalation powder (TreT) in healthy normal volunteers P. Smith (RTP, United States of America), C. Watkins (RTP, United States of America), K. Kraft (Danbury, United States of America), M. Grant (Danbury, United States of America)
PULSAR: A phase 2, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of sotatercept (ACE-011) when added to standard of care (SOC) for treatment of pulmonary arterial hypertension (PAH) D. Badesch (Aurora, United States of America), S. Gibbs (London, United Kingdom), M. Gomberg-Maitland (Washington DC, United States of America), M. Humbert (Le Kremlin-Bicetre, France), V. Mclaughlin (Ann Arbor, United States of America), I. Preston (Boston, United States of America), R. Souza (São Paulo, Brazil), A. Waxman (Boston, United States of America), J. De Oliveira Pena (Cambridge, United States of America), J. Barnes (Cambridge, United States of America), X. Zhang (Cambridge, United States of America), R. Zeldin (Cambridge, United States of America)
Digoxin effect in mortality associated to right ventricular dysfunction in patients with pulmonary hypertension H. Saucedo (Mexico City, Mexico), N. Zayas-Hernandez (Mexico City, Mexico), J. López-Flores (Mexico City, Mexico), T. Pulido-Zamudio (Mexico City, Mexico)
Hemodynamical effects of metformin and sildenafil in the treatment of experimental pulmonary hypertension V. Benavides (Cali, Colombia), M. Silva-Medina Weil (Cali, Colombia), S. Castaño (Cali, Colombia), M. Palacios (Cali, Colombia)
Evolution of patients with Pulmonary Arterial Hypertension (PAH) six months after an exercise training program C. Martin Ontiyuelo (Barcelona, Spain), A. Rodó Pin (Barcelona, Spain), I. Blanco (Barcelona, Spain), A. Herranz Blasco (Barcelona, Spain), L. Molina Ferragut (Barcelona, Spain), L. Piccari (Barcelona, Spain), J. Barberà (Barcelona, Spain), D. Rodríguez Chiaradía (Barcelona, Spain)
Physical activity levels in schistosomiasis associated-pulmonary arterial hypertension D. Da Silva Goncalves Bos (Sao Paulo, Brazil), L. Tamie Kato Morinaga (Sao Paulo, Brazil), R. Taminato Hirata (Sao Paulo, Brazil), A. Rocha Diniz Kimura (Sao Paulo, Brazil), A. Clara Tude Rodrigues (Sao Paulo, Brazil), J. Lazaro De Andrade (Sao Paulo, Brazil), R. De Souza (Sao Paulo, Brazil), C. R F Carvalho (Sao Paulo, Brazil)
Heterogeneity in lung 18F-FDG uptake in precapillary pulmonary hypertension J. Osorio Trujillo (Madrid, Spain), E. Agustí-Camprubí (Barcelona, Spain), I. Vollmer (Barcelona, Spain), J. Pavia (Barcelona, Spain), Y. Torralba (Madrid, Spain), P. Paredes (Barcelona, Spain), O. Tura-Ceide (Madrid, Spain), L. Sebastián (Barcelona, Spain), A. Ramírez (Madrid, Spain), V. Peinado (Madrid, Spain), I. Blanco (Madrid, Spain), J. Barberà (Madrid, Spain)
Platelets and pulmonary arterial hypertension (PAH) T. Oliveira (SP, Brazil), D. Calderaro (SP, Brazil), B. Piloto (SP, Brazil), M. Castro (SP, Brazil), S. Hoette (SP, Brazil), C. Jardim (SP, Brazil), R. Souza (SP, Brazil), C. Fernandes (SP, Brazil)
A retrospective review of computed tomography (CT) findings in Eisenmenger Syndrome and their prognostic implications S. Sathianandan (London, United Kingdom), B. Rawal (London, United Kingdom), H. Nashat (London, United Kingdom), L. Price (London, United Kingdom), S. Padley (London, United Kingdom), K. Dimopoulos (London, United Kingdom), T. Semple (London, United Kingdom), J. Wort (London, United Kingdom)
Impact of ILD severity and subtype on outcomes in CTD-associated PAH R. Hastings (London, United Kingdom), S. Mahboobani (London, United Kingdom), A. Kempny (London, United Kingdom), K. Dimopoulos (London, United Kingdom), C. Mccabe (London, United Kingdom), A. Devaraj (London, United Kingdom), A. Wells (London, United Kingdom), S. Wort (London, United Kingdom), L. Price (London, United Kingdom)
The role of cardiopulmonary exercise testing in assessment of the severity of patients with PAH associated with congenital heart disease. S. Gratsianskaia (Moscow, Russian Federation), Z. Valieva (Moscow, Russian Federation), I. Taran (Moscow, Russian Federation), T. Martynyuk (Moscow, Russian Federation)
Prevalence and echocardiographic screening for pulmonary hypertension in liver transplantation recipients J. Nakamura (Sapporo, Japan), H. Ohira (Sapporo, Japan), A. Sugimoto (Sapporo, Japan), T. Nakaya (Sapporo, Japan), N. Suzuki (Sapporo, Japan), A. Hyashishita (Sapporo, Japan), T. Sato (Sapporo, Japan), T. Watanabe (Sapporo, Japan), H. Iwano (Sapporo, Japan), N. Kawamura (Sapporo, Japan), T. Shimamura (Sapporo, Japan), I. Tsuzino (Sapporo, Japan)
Physician/patient reporting of depression/anxiety in a US pulmonary arterial hypertension population M. Hanson (Bollington, United Kingdom), M. Small (Bollington, United Kingdom)
A decade of activity in treating patients with pulmonary arterial hypertension in Timisoara center L. Pîslaru (Timisoara, Romania), N. Bertici (Timisoara, Romania)
Survival analysis of PAH patients based on a multidimensional risk approach at baseline in Uruguay: 10 years of experience of a PH referral centre. J. Grignola (Montevideo, Uruguay), A. Gruss (Montevideo, Uruguay), G. Pascal (Montevideo, Uruguay), C. Chao (Montevideo, Uruguay), J. Salisbury (Montevideo, Uruguay), C. Bedo (Montevideo, Uruguay), A. Coppola (Montevideo, Uruguay), B. Janssen (Montevideo, Uruguay), P. Trujillo (Montevideo, Uruguay), P. Curbelo (Montevideo, Uruguay)
Pulmonary hypertension in hereditary hemorrhagic telangiectasia is associated with multiple clinical conditions V. Margelidon-Cozzolino (Bron, France), V. Cottin (Bron, France), S. Dupuis-Girod (Bron, France), K. Ahmad (Bron, France), J. Traclet (Bron, France), J. Glérant (Bron, France), J. Mornex (Bron, France), S. Turquier (Bron, France)